The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Watson, Crick, Wilkins and Franklin all worked in MRC laboratories. Crick and Watson felt that they had benefited from collaborating with Wilkins. They offered him a co-authorship on the article that first described the double helix structure of DNA. Wilkins turned down the offer, a fact that may have led to the terse character of the acknowledgement of experimental work done at King's College in the eventual published paper. Rather than make any of the DNA researchers at King's College co-authors on the Watson and Crick double helix article, the solution that was arrived at was to publish two additional papers from King's College along with the helix paper. Brenda Maddox suggests that because of the importance of her experimental results in Watson and Crick's model building and theoretical analysis, Franklin should have had her name on the original Watson and Crick paper in Nature. Franklin and Gosling submitted their own joint "second" paper to Nature at the same time as Wilkins, Stokes, and Wilson submitted theirs (i.e. the "third" paper on DNA). Watson's portrayal of Franklin in The Double Helix was negative and gave the appearance that she was Wilkins' assistant and was unable to interpret her own DNA data. However, according to Nathaniel C. Comfort, a historian of medicine at Johns Hopkins University, Franklin's colleague Aaron Klug believed that Franklin "..was 'two steps away' from the double helix. After completing an analysis of her lab notebook, Klug stated that she surely would have had it.
The repository reportedly contained Nissan NA mobile apps, parts of the Nissan ASIST diagnostics tool, Nissan's internal core mobile library, Dealer Business Systems and Dealer Portal, client acquisition and retention tools, market research tools and data, vehicle logistics portal, vehicle connected services, and various other back ends and internal tools, they reported. On February 10, 2021, Cyberpunk 2077 and Witcher 3 developer CD Projekt Red (CDPR) announced hackers had targeted the company and attempted to hold it to ransom. On 6 June 2021, someone in possession of the data had leaked all of Cyberpunk 2077 code (96.02 GB of data in 7z archive) online publicly, while previously it was only available in encrypted form. On October 6, 2021, streaming site Twitch had its source code along with earnings reports of top streamers leaked by hackers on 4chan, citing the streaming site's negative community and desire for competition and disruption of the online video streaming space. The breach was confirmed by Twitch on X. The leak was distributed freely via a torrent file and was 135.17 GB in size. As a precaution, all the stream keys have been reset by Twitch. On February 25, 2022, ransomware group LAPSUS$ hacked NVIDIA and reportedly obtained 1 TB of proprietary information. The group subsequently released a ~20 GB archive containing the source code for NVIDIA GPU drivers among other things. Details for a Nintendo Switch successor (Switch 2) were also found among the data.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{232}_{90}Th->[\alpha ][1.40\times 10^{10}\ {\ce {y}}]{^{228}_{88}Ra}->[\beta ^{-}][5.75\ {\ce {y}}]{^{228}_{89}Ac}->[\beta ^{-}][6.15\ {\ce {h}}]{^{228}_{90}Th}->[\alpha ][1.9125\ {\ce {y}}]{^{224}_{88}Ra}->[\alpha ][3.632\ {\ce {d}}]{^{220}_{86}Rn}}}\\{\ce {^{220}_{86}Rn->[\alpha ][55.6\ {\ce {s}}]{^{216}_{84}Po}->[\alpha ][144.0\ {\ce {m}}s]{^{212}_{82}Pb}->[\beta ^{-}][10.627\ {\ce {h}}]{^{212}_{83}Bi}}}{\begin{Bmatrix}{\ce {->[64.06\%\beta ^{-}][60.55\ {\ce {min}}]{^{212}_{84}Po}->[\alpha ][294.4\ {\ce {ns}}]}}\\{\ce {->[35.94\%\alpha ][60.55\ {\ce {min}}]{^{208}_{81}Tl}->[\beta ^{-}][3.053\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{208}_{82}Pb}}\end{array}}}
Sources: en.wikipedia.org
=== 2017: Two Masters titles, world No. 3 === During the 2017 season, Zverev greatly improved his results at the higher level tournaments on the ATP Tour except for the four major events. It was at this time Zverev, who had been using his nickname Sascha, stated in a postmatch interview with Pam Shriver, that he would no longer be referred to as Sascha. Zverev stated that only his close family can refer to him as Sascha, as he was born in Germany and identifies as a German, and does not want a Russian nickname to be used for his professional career. At the Australian Open, Zverev again pushed Rafael Nadal to the brink, but ultimately lost in five sets. His next ATP tournament was the Open Sud de France, where he won both the singles and doubles events. He and his brother defeated Fabrice Martin and Daniel Nestor for Alexander's first doubles title. The following month, he made his first Masters quarterfinal at the Miami Open, upsetting No. 3 Stan Wawrinka along the way. Nick Kyrgios defeated him at both Masters events that month. After a slow start to the clay court season, Zverev won two more titles in May, the first of which came at home in Germany at the Bavarian International Tennis Championships. He then followed up a second Masters quarterfinal at the Madrid Open with his first Masters title at the Rome Masters. He defeated Novak Djokovic in the final to become the youngest Masters champion since Djokovic in 2007 and the first such champion born in the 1990s. With the title, he also entered the top 10 for the first time.
=== Dextran hydrogel applications === Dextran hydrogel and dextran conjugate hydrogel drug delivery systems have a variety of applications. These gels can be used to release therapeutics to treat cancer, swelling, inflammation, bone diseases, and infections.
Intestinal desmosis is a medical condition implicated in gut motility disorder and chronic constipation. Desmosis can be observed as the absence of the tendinous plexus layer and connective tissue fibers.
Sources: en.wikipedia.org
== Epidemiology == While episcleritis is a common disease, its exact prevalence and incidence are unknown. It typically affects young or middle aged women. The diffuse form of episcleritis (70%) is more common than the nodular form (30%). One retrospective study found 28 percent of individuals with episcleritis experienced recurrent episodes of the disease.
With an increased public awareness and concern regarding radioactive contamination, there has been an increased interest in the development of new pathways for the capture, containment, and disposal of nuclear waste, which has largely been generated through the operation of nuclear power plants and continued decommissioning of nuclear weapons. One of the largest challenges currently recognized within the nuclear waste sector is the development and synthesis of novel materials capable of long-term containment and selective capture of actinides. Thus, metal-organic frameworks have emerged as a promising material towards this application; their remarkable modularity, high surface area, selective binding affinities, and customizable topology/crystallinity allow for a material with tunable, on-demand properties and high structural stability. These properties allow for the design of a framework that connects material properties with changes in structure at the atomic level, providing insight into the processes that these materials rely upon. For example, metal-organic frameworks tend to have high structural stability, as evidenced by their crystallinity. This has been applied towards nuclear waste by demonstrating that metal-organic frameworks, specifically a zirconium-based framework, resist prolonged exposure to gamma-rays, a deeply penetrating, hazardous form of radiation known to be emitted by radioactive substances such as 241Am, while retaining crystallinity. There are several known methods by which metal-organic frameworks have been used to sequester radionuclides.
The pools of A, B, and C have delta values defined as δA, δB, and δC respectively. These values are related to the ratio of heavy to light isotopes in each pool, and are the conventional means by which scientists express the isotopic composition of materials. Importantly, δB is distinct from δb listed on the diagram, as δb is the isotopic composition of B produced from A before it mixes with the pool of B. The isotopic compositions of the pools and products are related through fractionation factors that reflect the kinetic isotope effects (KIEs) associated with each reaction. For A → B,
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.